Physician profile
Laura Purdom
NPI 1821282997
$1,594.64
in general payments reported to CMS, 2019-2025
26 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $190 · 2021: $260 · 2022: $322 · 2023: $122 · 2024: $244 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.83 | 2019-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $265.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.18 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $141.19 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $91.14 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $68.90 | 2019-2022 | |
| Abbvie INC. | $63.23 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $61.26 | 2019-2021 | |
| Dexcom, INC. | $41.91 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.31 | 2019-2022 | |
| Boston Scientific Corporation | $36.59 | 2025 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $35.36 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.25 | 2022 | |
| Nestle Healthcare Nutrition INC. | $31.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $30.80 | 2025 | Airsupra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.03 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2025 | |
| Krystal Biotech INC | $18.52 | 2024 | Vyjuvek |
| Neurocrine Biosciences, INC. | $17.26 | 2025 | |
| Merck Sharp & Dohme LLC | $14.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.61 | 2020 | |
| Amarin Pharma, INC. | $14.31 | 2020 | |
| Abiomed | $13.95 | 2025 | |
| Eisai INC. | $13.28 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Purdom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.